SBMD is a “place = platform” where individuals and companies interested in drug discovery and medical devices gather.

As members of the research and development team of SBMD, the world’s foremost opinion leaders are participating in this platform.
SBMD expects the platform to be used as an open platform.

SBMD aims to build a mechanism to conduct joint development and provide research support, as well as procure financial aid and funding in various stages, from idea to seeds, seeds to patents / know-how, patents / know-how to pre-clinical research and development, from pre-clinical research and development to Phase I, II, and III Clinical Trials and further onto commercialization and marketing.

SBMD has wide clinical network that supports such activities.
SBMD aims to become a global leader in drug discovery through these platform activities.
SBMD is waiting for your participation. We welcome you!

SBMD has the following foremost opinion leaders of the world participating with us.

Through SBMD’s knowledge base, experience, human network, and leadership, we aim to become a global leader in the field of drug discovery by deepening and widening the scope of drug discovery, including drugs for treating lung cancer, and expanding the domain.

In collaboration with Shengbiao (Shanghai), SBMD has a tie up with the following universities and affiliated hospitals to promote pre-clinical and clinical research (data accumulation etc.) for the research and development and application of new pharmaceuticals and medical devices including lung cancer treatments.         

School of Medicine and Hospital, Tongji University of Shanghai
School of Medicine and Hospital, Shanghai Jiao Tong University
School of Medicine and Hospital, Fudan University of Shanghai
School of Medicine and Hospital, Shanghai Medical University

In the Shanghai Pulmonary Hospital of Tongji University, the Thoracic Surgery Group led by Dr. Yang Yang, the director of our company (Associate Professor of Shanghai Pulmonary Hospital, Tongji University), has been conducting double-lung
transplantation surgery, which is considered a difficult surgery worldwide, with a high success rate (20 to 30 cases).

In Japan, SBMD is making public relation activities and selling the following medical devices that Shengbiao(Shanghai) and Ushio Electronics (Suzhou) are jointly developing.

• 4/19  The bispecific molecular targeted drug “YY0411” that is being developed by our company as a specific medicine for lung cancer was appraised as an innovative treatment that would significantly reform lung cancer treatment. It was featured in the international academic journal “nature” titled “ADVERTISEMENT FEATURE” (based on nature’s scientific papers “Scientific Reports" published on January 7, 2016 and October 30 of the same year), issued on April 19th.

• ---

• 4/30  We have entered into an agreement with Tongji University (Shanghai, China) for the pre-clinical research and development in drug discovery, including that of YY0411. 
  

  ---

• 5/18  After opening a new office on the 12^th floor of Tokyo Marunouchi North Bldg., we have been working in full-swing since May 2018.

• ---

• 5/18  We have arranged to host a presentation and reception about our innovative lung cancer treatment “YY0411”.

• 6/1  With respect to “YY0411”, we visited the Pharmaceutical Safety and Evaluation Division of the Ministry of Health, Labour and Welfare to have advice on the early application process for authentication tests, how international multicenter clinical trials should be structured and undertaken, the preparation of an investigator’s brochure using pre-clinical data, the production of protein, and the requirements for the early-approval system.

• ---

• 6/19  With respect to “YY0411”, we visited PMDA (Pharmaceutical and Medical Devices Agency) to have advice on the preparation of the investigator’s brochure and clinical-trial protocol, as well as the global multicenter clinical trials and early approval / conditional approval.

• ---

• 8/29  With respect to “YY0411”, we visited PMDA to have advice on requirement patients and hospital number,and conditions of the medicines using clinical trials, and other conditional matters to clinical trials Phase I.

• ---

• 10/21 The new medicine of anti-lung cancer bispecific antibody YY0411 of our company, which has already been published on Nature, is invited to be published on Advanced Materials (Impact Factor 21.98). Currently, the project of this new medicine has stepped into the Clinical PhaseⅠand receives heated concern and support from International Study of Lung Cancer.
  YY0411 is invited to be published on Wiley, which is one of the top academic medicines in the world.
  website: https://onlinelibrary.wiley.com/doi/full/10.1002/adma.201805437

  ---

  10/27 ESTS(European Society of Thoracic Surgeons) announced that Dr.Yang Yang (Director of Sun-Bio Medical Device Co.,Ltd. and associate Professor of Tonji University) was award winner of the most honourable Prize of “Rafael Hervada” to Biomedical Recerch for the first signatory of “YY0411” , A Novel Bispecific Antibody(Anti-HER2 and Anti-VEGF)Drug.
  The awarding ceremony of the prize to the winner will take place 23th November in Spain.

  ---

11/25 “Rafael Hervada” award ceremony was held in La Coruna city in Spain, Dr.Yang Yang, Professor of Tonjing University and also director of our company, as an inventor of “YY0411”, and Mr. Keishiro Fukushima, chairman of our company, as a representative of the patentees attended the ceremony.